Pharmacy benefit managers overcharged for specialty generic medications — in many cases by hundreds and thousands of percent ...

Pharmacy benefit managers are the middlemen in the prescription drug market. The Federal Trade Commission reports the revenue of four PBMs exceeds $1 trillion and they control 86% of the market.

Mintz’s Health Law and Antitrust teams actively monitor federal and state regulatory and legislative developments in the PBM ...

In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus.

In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus.

The report shows that PBMs made over $7.3 billion in extra profits from dispensing specialty generic drugs during the study ...

In the days leading up to President Trump’s inauguration, the Biden FTC rushed to initiate major lawsuits and to tie a bow on ...

Carl Schmid, executive director of the HIV+Hepatitis Policy Institute in Washington, D.C., talks about the problems associated with generic HIV PrEP drug markups and potential ways to fix it.

Oil and gas production in the United States is hitting record highs, easily outpacing consumption growth and fueling an export boom that in 2020 achieved the country's first trade surplus in energy ...

An earlier FTC report published in July 2024 argued that the six largest PBMs were effectively running a monopoly that gave them enormous power over the price of medicines and allowed them to ...

The lawsuit – which has been anticipated since the FTC published a damning report on the PBM sector in July – names CVS Health's Caremark, UnitedHealth Group's Optum, and Cigna's Express ...

Drugmakers hope to see efforts that focus more on cracking down on pharmacy benefit managers while promoting drug innovation ...